6XTK
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6xtk by Molmil](/molmil-images/mine/6xtk) | Y114C Transthyretin structure in complex with Tolcalpone | Descriptor: | Tolcapone, Transthyretin | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | Deposit date: | 2020-01-16 | Release date: | 2020-05-13 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Febs J., 288, 2021
|
|
8PMA
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8pma by Molmil](/molmil-images/mine/8pma) | Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
8PMO
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8pmo by Molmil](/molmil-images/mine/8pmo) | Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-29 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.24 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
7QC5
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7qc5 by Molmil](/molmil-images/mine/7qc5) | Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2021-11-22 | Release date: | 2022-11-30 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation. J.Med.Chem., 65, 2022
|
|
5LCN
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5lcn by Molmil](/molmil-images/mine/5lcn) | |
8BQ3
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8bq3 by Molmil](/molmil-images/mine/8bq3) | |
8PM8
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8pm8 by Molmil](/molmil-images/mine/8pm8) | V30M Transthyretin structure in complex with Tolcalpone | Descriptor: | Tolcapone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.57 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
8PM9
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8pm9 by Molmil](/molmil-images/mine/8pm9) | Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
6TXW
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6txw by Molmil](/molmil-images/mine/6txw) | V30G Transthyretin structure in complex with Tolcalpone | Descriptor: | Tolcapone, Transthyretin | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | Deposit date: | 2020-01-14 | Release date: | 2020-05-13 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.153 Å) | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Febs J., 288, 2021
|
|
6TXV
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6txv by Molmil](/molmil-images/mine/6txv) | A25T Transthyretin structure in complex with Tolcalpone | Descriptor: | Tolcapone, Transthyretin | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | Deposit date: | 2020-01-14 | Release date: | 2020-05-13 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Febs J., 288, 2021
|
|
6FWW
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6fww by Molmil](/molmil-images/mine/6fww) | GFP/KKK. A redesigned GFP with improved solubility | Descriptor: | Green fluorescent protein | Authors: | Varejao, N, Lascorz, J, Gil-Garcia, M, Diaz-Caballero, M, Navarro, S, Ventura, S, Reverter, D. | Deposit date: | 2018-03-07 | Release date: | 2018-08-01 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.131 Å) | Cite: | Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility. Mol. Pharm., 15, 2018
|
|
6FXU
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6fxu by Molmil](/molmil-images/mine/6fxu) | |
5FO2
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5fo2 by Molmil](/molmil-images/mine/5fo2) | Structure of human transthyretin mutant A108I | Descriptor: | TRANSTHYRETIN | Authors: | Varejao, N, Santanna, R, Saraiva, M.J, Gallego, P, Ventura, S, Reverter, D. | Deposit date: | 2015-11-17 | Release date: | 2016-11-30 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.449 Å) | Cite: | Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Sci Rep, 7, 2017
|
|
5G5C
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5g5c by Molmil](/molmil-images/mine/5g5c) | |
5G59
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5g59 by Molmil](/molmil-images/mine/5g59) | |
5G5M
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5g5m by Molmil](/molmil-images/mine/5g5m) | |
7P47
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7p47 by Molmil](/molmil-images/mine/7p47) | Structure of the E3 ligase Smc5/Nse2 in complex with Ubc9-SUMO thioester mimetic | Descriptor: | E3 SUMO-protein ligase MMS21, SUMO-conjugating enzyme UBC9, Structural maintenance of chromosomes protein 5, ... | Authors: | Lascorz, J, Varejao, N, Reverter, D. | Deposit date: | 2021-07-09 | Release date: | 2021-11-24 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (3.314 Å) | Cite: | Structural basis for the E3 ligase activity enhancement of yeast Nse2 by SUMO-interacting motifs. Nat Commun, 12, 2021
|
|
6FZL
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6fzl by Molmil](/molmil-images/mine/6fzl) | |
6FWD
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6fwd by Molmil](/molmil-images/mine/6fwd) | |
5FW6
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5fw6 by Molmil](/molmil-images/mine/5fw6) | Structure of human transthyretin mutant A108V | Descriptor: | TRANSTHYRETIN | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2017-03-08 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Sci Rep, 7, 2017
|
|
5FW7
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5fw7 by Molmil](/molmil-images/mine/5fw7) | Structure of human transthyretin mutant A109V | Descriptor: | TRANSTHYRETIN | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2017-03-08 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Structure of New Non-Amyloidogenic Mutant of Ttr A108V To be Published
|
|
5FW8
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5fw8 by Molmil](/molmil-images/mine/5fw8) | Structure of human transthyretin mutant E89K | Descriptor: | TRANSTHYRETIN | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2016-12-28 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Structure of New Non-Amyloidogenic Mutant of Ttr A108V To be Published
|
|